Nanotech Systems Inc.
Nanotech Systems Inc.: Appointment of Dr. David Scratchley as Chief Executive Officer
Nanotech Systems Inc. / Key word(s): Change of Personnel SEATTLE, Washington, March 24, 2011, Nanotech Systems Inc. announces the appointment of Dr. David Scratchley as Chief Executive Officer of the company effective March 19, 2011. Catherine Soncrant has stepped down from the CEO position and into the VP of Marketing effective immediately. As Ms. Soncrant stated 'As the company begins to mature and is positioned to evolve from a research and development organization into a true production company, it was important that our senior leadership have the background and understanding of the clinical trial process on a global scale and Dr. Scratchley brings tremendous experience and understanding to guide us in the right direction.' With nearly 20 years' experience in directing clinical research and the operations of a Clinical Trial Network, comprised of clinical, data, statistical, financial, quality assurance, and investigational pharmacy services, Dr. Scratchley has conducted Phase I, II, and III trials in over seventy medical school hospital clinics. As the Director of Operations for Seattle Children's Hospital, he ran the clinical trial network and built a platform of knowledge in introducing new pharma products and technologies. Prior to this Dr. Scratchley served on the faculty at Seattle University and served as a Project Director at Axio Research. According to Dr. Scratchley, 'I am truly excited to work with the team and resources that Nanotech has worked diligently in building and to participate in revolutionizing drug delivery systems in the field of diabetes treatment is an opportunity to change the face of medicine and treatment. Leading Nanotech, I am committed to exploring our global partners in developing technology for market. I am honored to be part of this organization and to work with our brethren in Europe to continue to evolve our business.' About Nanotech Systems, Inc. Nanotech Systems ,Inc. (FWB: N95) is a materials science company developing unique and proprietary processes for delivery of pharmaceutical products intra body with reactive qualities and efficiencies to affect the diseased or compromised cells. With applications to medicine and physiology, Nanotech Systems is developing materials and devices designed to interact with the body at a subcellular scale with a high degree of specificity. Nanotech Systems targets cellular and tissue specific clinical applications designed to achieve maximal therapeutic affect with minimal side effects. Nanotech uses its broad intellectual property rights and proprietary know-how to establish application trials and testing for commercial application at both the academic and corporate level with programs throughout the U.S. and Canada and expansion into Europe. For more information, please visit www.nano-techgroup.com. This press release is for informational purposes only and does not constitute, or form part of an offer to buy of the solicitation of any offer to sell any securities in any jurisdiction not shall it (or any part of it), or the fact of its distribution, form the basis of or be relied on in connection with any contract therefore. End of Corporate News 25.03.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
117045 25.03.2011 |